# Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

> **NCT00187174** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 41 (actual)

## Conditions studied

- Tumors
- Brain Tumors
- Rhabdomyosarcoma
- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00187174
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00187174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00187174, "Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00187174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*